Edward A. Kolb

Edward A. Kolb

Hematology | Oncology

1600 Rockland Road
Wilmington, DE 19803

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 172 publications

AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group.

AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 24, 2026

Life-years saved by advances in blood cancer therapy: a retrospective analysis.

Life-years saved by advances in blood cancer therapy: a retrospective analysis.

Journal: Blood advances

Published: January 22, 2026

Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors.

Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 12, 2025

DLK1 is a GATA1s-driven dependency and therapeutic target in Down syndrome-associated myeloid leukemia.

DLK1 is a GATA1s-driven dependency and therapeutic target in Down syndrome-associated myeloid leukemia.

Journal: Blood advances

Published: October 20, 2025

DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid Leukemia.

DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid Leukemia.

Journal: Blood advances

Published: October 20, 2025

Mesothelin promotes acute myeloid leukemia progression through LYN-dependent signaling.

Mesothelin promotes acute myeloid leukemia progression through LYN-dependent signaling.

Journal: The Journal of biological chemistry

Published: September 04, 2025

Molecular Risk Markers Define Risk of Relapse in Myeloid Leukemia of Down syndrome Beyond Measurable Residual Disease.

Molecular Risk Markers Define Risk of Relapse in Myeloid Leukemia of Down syndrome Beyond Measurable Residual Disease.

Journal: Blood advances

Published: July 22, 2025

Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease.

Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease.

Journal: Blood advances

Published: July 22, 2025

Erratum: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.

Erratum: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 14, 2025

Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia.

Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia.

Journal: JAMA network open

Published: June 23, 2025

Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.

Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 28, 2025

Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel.

Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel.

Journal: Blood

Published: March 31, 2025

Showing 1-12 of 172

Last Updated: 09/26/2026